Healio Minute

In this edition, foslevodopa-foscarbidopa improves motor symptoms in advanced PD, posterior surgery for treating cervical radiculopathy, Tysabri favored over IV in patients with relapsing-remitting MS and more.

Read the full coverage here:

Continuous subcutaneous foslevodopa-foscarbidopa improves motor symptoms in advanced PD

Posterior surgery noninferior to anterior for treating cervical radiculopathy

Subcutaneous delivery of Tysabri favored over IV in patients with relapsing-remitting MS

NeuroLogica receives FDA clearance for multiuse imaging tool

Vumerity effective over 96 weeks in patients with relapsing-remitting MS

References:

Broekema AEH, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.4208.

Gold R, et al. SISTER – subcutaneous: non-interventional, observational, prospective, German multicenter, open-label study over 12-months for Tysabri patient preference – experience from real world – preliminary results of the 1st interim analysis. Presented at: ECTRIMS 2022; Oct. 26-28; Amsterdam.

Press Release

Singer BA, et al. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Presented at: ECTRIMS 2022; Oct. 26-28; Amsterdam.

Soileau MJ, et al. Lancet Neurol. 2022;doi:10.1016/S1474-4422(22)00400-8.

In this edition, risk factors linked to PD, digital brain health platform offers dementia risk assessment, Klotho protein levels linked to Alzheimer's and more.

Read the full coverage here:

Tremor, restless legs syndrome, schizophrenia among risk factors linked to PD

Digital brain health platform offers rapid, accurate assessment of dementia risk

Klotho protein levels linked to Alzheimer's, cognitive decline, amyloid and tau burden

Body temperature irrigation for chronic subdural hematoma should be 'standard of care'

FDA requests additional information, extends goal date for application of MS treatment

References:

Bartley A, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.4133.

Grøntvedt GR, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.43232.

Press Conference

Press Release

Schrag A et al. JAMA Neurology. 2022;doi:10.1001/jamaneurol.2022.3902.

In this edition, disparities among women in the surgical workforce, GSK withdraws belantamab mafodotin from US market, risk for lymphoma low after postmastectomy reconstruction, and more.

Read the full coverage here:

More women surgeon scientists receive NIH funding than in 2010, yet gender gaps remain

GSK to withdraw multiple myeloma therapy from US market

Risk for lymphoma after postmastectomy breast implant reconstruction 'still extremely low'

Differences observed in adverse events of antibody-drug conjugates

FDA approves Hemgenix as first gene therapy for treatment of hemophilia B

References:

Kinslow CJ, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.43396.

Press Release

Press Release

Saif A, et al. JAMA Surg. 2022;doi:10.1001/jamasurg.2022.5157

Zhu Y, et al. Cancer. 2022;doi:10.1002/cncr.34507.

In this edition, lung cancer screening critically low across the U.S, first in-human CRISPR test with gene replacement, racial and economic segregation linked to higher cancer mortality rates, and more.

Read the full coverage here:

Lung cancer screening rates in US 'simply unacceptable'

First CRISPR-based cell therapy to use gene replacement feasible, safe for solid tumors

Racial, economic segregation linked to cancer mortality

Onivyde regimen extends OS in metastatic pancreatic ductal adenocarcinoma

Immunotherapy a 'significant improvement' for treatment of multiple myeloma

References:

Davies FE, et al. New therapeutic agents for relapsed/refractory multiple myeloma: CAR T and bispecific antibodies. Presented at: 40th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow; Nov. 9-11, 2022.

Foy SP, et al. Abstract 1478. Presented at: Society for Immunotherapy of Cancer Annual Meeting; Nov. 8-12, 2022; Boston.

Press Release

Press Release

Zhang L, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5382.

In this edition, best practice statements for celiac disease; older patients with IBD at risk for treatment failure with vedolizumab; Follow-up surveillance for post-colonoscopy CRC and more.

Read the full coverage here:

AGA releases 10 best practice statements for management of refractory celiac disease

Older patients with IBD at higher risk for treatment failure with vedolizumab

Follow-up surveillance within 5 years may detect post-colonoscopy CRC

Bulevirtide maintains safety, efficacy in HDV-related compensated cirrhosis at 72 weeks

PLX065 reduces liver fat content, prevents worsening of fibrosis in NASH

References:

Degasperi E, et al. Extension of bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the Italian multicenter study (HEP4Di). Presented at: The Liver Meeting; Nov. 4-8, 2022; Washington (hybrid).

Green PHR, et al. Gastroenterology. 2022;doi:10.1053/j.gastro.2022.07.086

Harrison SA, et al. PLX065 (deuterium-stabilized r-enantiomer of pioglitazone) reduces liver fat content and improves liver histology without PPAR gamma-mediated side effects in patients with NASH: Analysis of a 36-week placebo-controlled phase 2 trial (DESTINY1). Presented at: The Liver Meeting; Nov. 4-8, 2022; Washington (hybrid meeting).

Imperiale TF, et al. Abstract S245: Risk factors for 5-year post-colonoscopy colorectal cancers (PCCRCs). Presented at: ACG Annual Scientific Meeting; Oct. 21-26, 2022; Charlotte, N.C. (hybrid meeting).

Singh S, et al. JAMA Netw Open. 2022;doi: 10.1001/jamanetworkopen.2022.34200.

In this edition, the importance of vaccination after cell therapy, artificial intelligence may help predict cardiotoxicity, experimental breast cancer vaccine generates immune response, and more.

Read the full coverage here:

Revaccination guidance after cell therapy established for some, 'evolving' for others

Artificial intelligence may help predict cardiotoxicity in renal cell carcinoma

Experimental breast cancer vaccine generates immune response to key tumor protein

Cancer cell therapy for melanoma has potential to save 'thousands' of lives each year

CAR-T regimen 'should be new standard' for high-risk B-cell acute lymphoblastic leukemia

References:

Disis ML, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5143.

Sarnaik A, et al. Abstract 789. Presented at: Society for Immunotherapy of Cancer Annual Meeting; Nov. 8-12, 2022; Boston.

Saullo JL, et al. The importance of re-vaccination after cellular therapy. Presented at: NCCN 2022 Annual Congress: Hematologic Malignancies; Oct. 14-15, 2022; New York.

Wang T, et al. J Clin Oncol. 2022;doi:10.1200/JCO.22.01214

Yasin H, et al. Abstract 16. Presented at: International Kidney Cancer Symposium: North America; Nov. 4-5, 2022; Austin, Texas.

In this edition, neurologic effects of COVID-19 among pediatric populations, FDA accepts NDA for extended-release carbidopa/levodopa, antihistamines could be promising therapy for Parkinson's disease and more.

Read the full coverage here:

Neurologic effects of COVID-19 persisted among pediatric populations in 2021

FDA accepts NDA for extended-release carbidopa/levodopa Parkinson's treatment

Antihistamines could be promising adjuvant therapy for Parkinson's disease

Recurrent head injury linked to affective dysregulation, impulse control

AI-powered detection tool found 85% of aneurysms were not referred for follow-up

References:

LaRovere KL, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.3881.

Press Release

Press Release

Richey LN, et al. M240. Associations of prior head injury with mild behavioral impairment domains. Presented at: American Neurological Association annual meeting; Oct. 23-25, 2022; Chicago.

Tandra G, et al. M189. Literature-based discovery to assess Parkinson's disease adjuvants to levodopa. Presented at: American Neurological Association annual meeting; Oct. 23-25, 2022; Chicago.

In this episode, data show 'critical need' for universal genetic testing; patients with inflammatory breast cancer at high risk for brain metastases; palbociclib fails to benefit breast cancer subgroup and more.

Read the full coverage here:

Data show 'critical need' for universal genetic testing of patients with breast cancer

Patients with inflammatory breast cancer at high risk for brain metastases

Palbociclib fails to benefit breast cancer subgroup, yielding lessons for future research

Low-dose aspirin does not reduce breast cancer risk

Interventions improve cancer screening rates among women in rural areas

References:

Cairat M, et al. Abstract 1840. Presented at: World Cancer Congress; Oct. 18-20, 2022; Geneva.

DeMichele A, et al. Adjuvant palbociclib for ER+ breast cancer (PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A preplanned analysis of the stage IIA cohort. Presented at: ASCO Plenary Series; Oct. 18, 2022.

Paskett ED, et al. Abstract 1959. Presented at: World Cancer Congress; Oct. 18-20, 2022; Geneva.

Warren LEG, et al. Cancer. 2022;doi:10.1002/cncr.34441.

Whitworth PW, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.32787.

In this edition, FDA approves Tecvayli for multiple myeloma, radiation and hormone therapy slows progression of prostate cancer, and more.

Read the full coverage here:

FDA approves Tecvayli for advanced multiple myeloma

Adding radiation to hormone therapy slows progression of oligometastatic prostate cancer

Use of cannabis during cancer treatment may have 'under-appreciated' financial impact

Older cancer survivors at higher risk for bone fracture

Machine-learning approach using step counts predicts hospitalization during radiotherapy

References:

Chino F, et al. Abstract 24. Presented at: ASCO Quality Care Symposium; Sept. 30-Oct. 1, 2022; Chicago.

Friesner I, et al. Abstract 132. Presented at: American Society for Radiation Oncology Annual Meeting; Oct. 23-26, 2022; New Orleans.

Press Release

Rees-Punia E, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5153.

Tang C, et al. Abstract LBA 05. Presented at: American Society for Radiation Oncology Annual Meeting; Oct. 23-26, 2022; San Antonio.

In this edition, we bring you more news and Healio-exclusive interviews from the American Neurological Association Annual Meeting.

Read the full coverage here:

Diversity key to understanding genetics of neurodegenerative disease

Assessing chemical exposures key to understanding neuro diseases and disorders

VIDEO: Neurological complications can spur from certain infectious diseases

Age, specific pathology tied to shorter symptom duration in rapidly progressive dementia

Cognition in persons with epilepsy dependent on type, therapy model

References:

Asghar F et al. Cognition in persons with epilepsy: Differences based on disease type and therapy. Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago.

Cory-Slechta DA. Chemical exposures: The ignored environmental risk factors for neurodegenerative diseases and neurodevelopmental disorders. Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago.

Guerreiro R. The genetics of neurodegenerative diseases: from rare populations to common variants. Presented at: American Neurological Association annual meeting; Oct. 23-25, 2022; Chicago.

Lazar E, et al. Dissecting the neuropathological contributors to rapidly progressive dementia. Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago.

Saylor D, et al. A string of pearls: Key considerations in the care of neurological infections. Presented at: American Neurological Association annual meeting; Oct. 23-25, 2022; Chicago.